Literature DB >> 23283612

Gingival pain: an unusual side effect of ziprasidone.

Ashwati Raghunath1.   

Abstract

The patient is a 52-year-old man with schizophrenia who developed severe, unremitting gingival pain after his ziprasidone dosage was increased from 80 to 120 mg. His physical examination and laboratory findings were unremarkable. He did not have any extra-pyramidal side effects. His pain did not ameliorate after taking acetaminophen and non-steroidal anti-inflammatory drugs. As a last resort, the patient took benztropine and his pain subsided within half an hour. His ziprasidone dosage was decreased and the patient is currently doing well. He has not experienced gingival pain since his medication was adjusted.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23283612      PMCID: PMC3604257          DOI: 10.1136/bcr-2012-007577

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

Review 1.  Pain in Parkinson's disease.

Authors:  Ainhi D Ha; Joseph Jankovic
Journal:  Mov Disord       Date:  2011-09-23       Impact factor: 10.338

2.  Family history of primary movement disorders as a predictor for neuroleptic-induced extrapyramidal symptoms.

Authors:  Rebekka Lencer; Gunnar Eismann; Meike Kasten; Kemal Kabakci; Verena Geithe; Jenny Grimm; Christine Klein
Journal:  Br J Psychiatry       Date:  2004-12       Impact factor: 9.319

3.  First- and second-generation antipsychotics: learning from CUtLASS and CATIE.

Authors:  Rajiv Tandon; William T Carpenter; John M Davis
Journal:  Arch Gen Psychiatry       Date:  2007-08

Review 4.  Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis.

Authors:  Lisa Hartling; Ahmed M Abou-Setta; Serdar Dursun; Shima S Mousavi; Dion Pasichnyk; Amanda S Newton
Journal:  Ann Intern Med       Date:  2012-10-02       Impact factor: 25.391

5.  Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs.

Authors:  Michael J Peluso; Shôn W Lewis; Thomas R E Barnes; Peter B Jones
Journal:  Br J Psychiatry       Date:  2012-03-22       Impact factor: 9.319

6.  Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia.

Authors:  G Muscettola; G Barbato; S Pampallona; M Casiello; P Bollini
Journal:  J Clin Psychopharmacol       Date:  1999-06       Impact factor: 3.153

7.  Adverse Drug Events Related to Ziprasidone: A Meta-analysis of Randomized, Placebo-Controlled Trials.

Authors:  Catherine A Harrington; Clayton English
Journal:  Pharmacotherapy       Date:  2011-09       Impact factor: 4.705

Review 8.  Prevalence of pain in Parkinson's disease: a systematic review using the modified QUADAS tool.

Authors:  Martijn P G Broen; Meriam M Braaksma; J Patijn; Wim E J Weber
Journal:  Mov Disord       Date:  2012-01-09       Impact factor: 10.338

Review 9.  [Pain and sensory disturbance in Parkinson disease].

Authors:  Fumihito Yoshii
Journal:  Brain Nerve       Date:  2012-04

10.  Painful sensory symptoms in neuroleptic-induced extrapyramidal syndromes.

Authors:  P Decina; S Mukherjee; G Caracci; K Harrison
Journal:  Am J Psychiatry       Date:  1992-08       Impact factor: 18.112

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.